亚洲社会药学

本期目录

2022年, 第17卷, 第3期　刊出日期：2022-09-25 上一期    下一期

Select

Considerations on the Quality Standards Reflecting the Characteristics of Compound Preparations of Traditional Chinese Medicine Zhao Wei, Wu Zhi’ang 2022 (3):  199-203.  摘要 ( 250 )   PDF(821KB) ( 218 )   Objective To study the current quality standard of traditional Chinese medicine (TCM) and its limitations in China, and encourage enterprises to take more responsibility to promote the development of this industry. Methods Based on the analysis of the status quo and problems of the quality standard system of TCM, the quality control mode, as well as the problems found in the reevaluation after marketing, some suggestions were put forward for adjusting the current quality standard of TCM. Results and Conclusion Through strengthening the quality control of the source, and under the premise of ensuring the safety, effectiveness and stability of TCM, the quality standards of TCM can be improved greatly. 相关文章 | 计量指标

Select

Research on the Relationship between Cooperation Innovation Expenditure and Economic Output of China’s Pharmaceutical Industry Wang Qiuli, Chen Yuwen 2022 (3):  204-213.  摘要 ( 298 )   PDF(873KB) ( 216 )   Objective To empirically analyze the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry, and provide a reference for improving its economic benefits and the capability of cooperation innovation in the future. Methods The relevant data of China’s pharmaceutical industry from 2000 to 2016 was selected as a sample. Based on the co-integration theory, an error correction model was established to conduct Granger test of causality to study the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry. Results and Conclusion The cooperation innovation expenditure of China’s pharmaceutical industry has a significant positive impact on economic output. If cooperation innovation expenditure increases 1%, its economic output will go up by 1.7%. At the same time, the long-term promotion effect of cooperation innovation expenditure on economic output is more significant than the short-term effect. 相关文章 | 计量指标

Select

Comparative Study and Enlightenment on Innovation Achievements of Pharmaceutical Industry in Liaoning Province Tao Na, Tian Lijuan 2022 (3):  214-221.  摘要 ( 352 )   PDF(1291KB) ( 181 )   Objective To promote the innovation and development of pharmaceutical industry in Liaoning Province. Methods Literature study and comparative study were used to investigate the current situation and problems of innovation driven development of pharmaceutical industry in Liaoning Province by comparing data of Heilongjiang, Jilin, Shandong, and Jiangsu from four aspects of priority review and approval, consistency evaluation of generic drugs, new drugs on the market, and scientific and technological innovation achievements. Results and Conclusion In terms of innovation-driven development, pharmaceutical industry in Liaoning Province has the following problems, such as small scale, weak transformation of scientific and technological achievements, tough business environment, and single platform module of scientific and technological achievements. Combined with the actual development of pharmaceutical industry in Liaoning province, the government should give full play to its leading role and guide “Benxi Pharmaceutical Capital” to establish characteristic industrial cluster and incubation park. After high quality enterprises and high-level innovative talents get together, enterprises can analyze their actual situation to plan R&D layout, focusing on the input-output ratio. Meanwhile, the benign development of the enterprises, universities and research institutes should be promoted to integrate technical innovation and product supply. This can enhance the cooperation among the government, enterprise, university, and research institute, and provide reference for further development of pharmaceutical industry in Liaoning province. 相关文章 | 计量指标

Select

Experimental Design of Observational Studies in Real-World Study Qu Yi, Wang Yuzhuo, Yuan Xiaoliang, Wang Chuang, Huang Zhe, Chen Yuwen 2022 (3):  222-228.  摘要 ( 228 )   PDF(817KB) ( 259 )   Objective To introduce the design of observational trials under real-world study (RWS), and to provide guidance for clinical development of new research trials and reference for real-world researchers. Methods Relevant literature of RWS and observational experiments at home and abroad were reviewed and analyzed, and then the design of observational studies was summarized under RWS. Results and Conclusion The data and information provided in observational studies not only help to further verify the clinical study results obtained by randomized controlled trial (RCT) in clinical practice, but also objectively reflect the real situation in the process of clinical research and application. 相关文章 | 计量指标

Select

The Expanding Roles of Hospital Pharmacists in Clinical Drug Trials in China Zhao Shanshan, Zhang Boquan, Wang Hongyun 2022 (3):  229-235.  摘要 ( 354 )   PDF(789KB) ( 198 )   Objective To aim at summarizing the role of hospital pharmacists in clinical drug trials in China against the background that hospital pharmacists have already involved in team-based patient care. Methods The roles and responsibilities of Chinese hospital pharmacists were listed and categorized. Results and Conclusion There has been an upsurge in clinical drug trials in China. Hospital pharmacists play increasingly important roles in all aspects of clinical trials, such as stakeholder liaisons, protocol developers, ethics committee members, research team members, study drug managers, and subject intervention agents. Hospital pharmacists are an integral part of a clinical drug trial multidisciplinary team. Their value is reflected in several pharmacist-led or pharmacist-participating clinical trials as well as the trial project management position within hospitals. Pharmacists should be the designers, researchers, managers and supervisors of clinical drug trials. We expect that all clinical trial projects will include hospital pharmacists in their research teams soon. 相关文章 | 计量指标

Select

Research on Problems and Countermeasures of Patent Evaluation System in Pharmaceutical Enterprises Zeng Yingying, Shen Manzhu, Yuan Hongmei, Han Xu 2022 (3):  236-242.  摘要 ( 236 )   PDF(1078KB) ( 144 )   Objective To provide some suggestions and countermeasures for improving the patent evaluation system in pharmaceutical enterprises. Methods Literature research method was used to collect the relevant documents of pharmaceutical enterprises and patent evaluation system, and then the problems of traditional patent evaluation methods for pharmaceutical patents were studied. Results and Conclusion The evaluation of pharmaceutical patents plays an important role for pharmaceutical enterprises. However, it is urgent to improve the pharmaceutical patent evaluation system because there are many difficulties in evaluating pharmaceutical patents, such as large fluctuation of patent value, strong subjective interference, the incomplete pharmaceutical information, unapplicable traditional evaluation method, and the insufficient role of evaluation agencies. Therefore, some suggestions are put forward: (1) The application of the real option method; (2) Developing evaluation institutions and training evaluation personnel; (3) Improving the laws and policies related to the evaluation of pharmaceutical patents; (4) Building a pharmaceutical patent evaluation database. 相关文章 | 计量指标

Select

Research on the Price Level of Drugs in Short Supply in China Liu Fuyao, Sun Lihua 2022 (3):  243-252.  摘要 ( 287 )   PDF(5382KB) ( 134 )   Objective To determine the price level of drugs in short supply and conduct affordability evaluations, thus putting forward countermeasures and suggestions for the management of prices of these drugs. Methods Taking the national list of drugs in short supply and the national key monitoring list of clinically essential drugs in short supply as the research objects, the bid-winning prices were searched through various bidding websites across the country, and the price levels of the varieties in the list were evaluated through fixed base price index, median price ratio and other indicators. The per capita income evaluation method was used to evaluate the affordability of the drugs on the list. Results and Conclusion Among the 30 varieties with valid international reference prices, 25 are higher than the international reference prices. The prices of 14 kinds of drugs are 1-5 times higher than the international reference prices. The prices of 10 kinds of drugs are 6-35 times higher than the international reference prices. In rural and urban areas, 50% and 73% of the drugs in short supply cost more than two times of the daily income for each course of treatment. The current price levels of selected drugs in short supply are generally high. It is recommended that these drugs should be classified and managed. Besides, the shortage of drugs should be included in the centralized procurement organized by the state to solve the unstable supply in the market. 相关文章 | 计量指标

Select

Benefit-Risk Assessment for PD-1/PD-L1 Inhibitors in the Treatment of Non-Small Cell Lung Cancer Li Zhuangqi, Yang Yue 2022 (3):  253-259.  摘要 ( 329 )   PDF(1808KB) ( 207 )   Objective To explore the benefits and risks of PD-1/PD-L1 inhibitors Atezolizumab and Nivolumab in the treatment of non-squamous non-small cell lung cancer and provide some references for clinicians. Methods Based on the data results of relevant studies published by ClinicalTrical.gov in the US clinical trial database and foreign peer-reviewed journals, the internationally recognized multi-criteria decision analysis (MCDA) model was used to assess the benefit and risk of PD-1/PD-L1 inhibitors for non-squamous non-small lung cancer comprehensively. Finally, a sensitivity analysis was performed to test the sensitivity of the weight to the evaluation. Results and Conclusion The benefit-risk evaluation result of Atezolizumab for the treatment of non-squamous non-small cell lung cancer is better than that of Nivolumab. Specifically, Atezolizumab has more benefits than Nivolumab with a lower risk. The results of MCDA model in drug benefit and risk evaluation are easy to understand. However, the selection of indicators in the model and the degree of data acquisition are limited. The evaluation results of the MCDA model should be comprehensively viewed with other evaluations to make decisions objectively. 相关文章 | 计量指标

Select

Development Strategy of Green Marketing of Pharmaceutical Enterprises against the Background of Building a Beautiful China Wang Shuling, Wang Mingzheng, Yu Chang 2022 (3):  260-267.  摘要 ( 317 )   PDF(790KB) ( 225 )   Objective To study the key issues and links in the construction of green marketing for pharmaceutical enterprises combined with the law of scientific development, so as to make joint efforts for the construction of beautiful China. Methods The literature and interview methods were used to demonstrate that green civilization was to pursue the harmonious coexistence between environment and human beings. Besides, the responsibilities and problems that pharmaceutical enterprises faced in the context of building a beautiful China had to be solved urgently. Results and Conclusion China should summarize historical errors and face the current situation while building a beautiful country. In addition, pharmaceutical enterprises should clarify the key links of green marketing to solve the problem of “three wastes”. Meanwhile, they should bear other responsibilities to promote green civilization and social development. 相关文章 | 计量指标

Select

Analysis of Factors Affecting Online Drug Purchase – Based on Factor Analysis Wang Shuling, Liu Liang, Zhi Yuanyuan 2022 (3):  268-280.  摘要 ( 324 )   PDF(2843KB) ( 310 )   Objective To explore the factors affecting consumers’ online drug purchases, and construct models of these factors to provide references for the development and popularization of online pharmacies. Methods Through searching, classifying, integrating, and extracting evaluation indexes of online pharmacies in literature, the indexes of factors affecting online drug purchases were initially established. Then SPSS24.0 was used for data analysis, and finally factor analysis was applied for screening and combining the indexes. Results and Conclusion A model of influencing factors for online drug purchases is set up with 4 factors and 14 indexes. Convenient service is the most important factor affecting online drug purchases. Highly educated young people prefer to buy drugs online. At present, online drug purchase is only a supplement to the purchase of drugs in offline pharmacies, and the penetration rate is not high. Online pharmacies should give full play to their advantages in terms of drug types, prices, logistics and after-sales services to make online drug purchases more mainstream. 相关文章 | 计量指标